Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hematopoietic progenitor kinase 1 (HPK1) functions as a key negative regulator of T cell receptor signaling and has been considered a potential target for cancer immunotherapy. Despite great progress in developing HPK1 inhibitors, no small-molecule inhibitors have been approved for cancer treatment to date. Herein, we describe the design and synthesis of a novel series of macrocyclic 2,4-diaminopyrimidine derivatives as HPK1 inhibitors. Among these, the representative compound 21 exhibited potent HPK1 inhibition with an IC value of 1.0 nM in an ADP-Glo assay. Furthermore, compound 21 effectively inhibited phosphorylation of the downstream adaptor protein SLP76 and enhanced IL-2 secretion in human Jurkat T cells. Taken together, this study further validates macrocyclization as an effective strategy for designing HPK1 inhibitors with innovative scaffolds and offers compound 21 as a structurally novel lead compound for the development of HPK1 inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2025.118265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, synthesis, and biological evaluation of 2-substituted-pyridin-4-yl macrocyclic derivatives as new selective HPK1 inhibitors.
Bioorg Chem
August 2025
State Key Laboratory of Green Pesticide, Central China Normal University, Wuhan, 430079, PR China.
Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of T-cell receptor (TCR) signaling and a promising therapeutic target in immunotherapy. Herein, based on the reported HPK1 inhibitor Compound K, a series of 2-substituted-pyridin-4-yl macrocyclic HPK1 inhibitors was designed and synthesized through structure-based drug design and macrocyclization strategies. Detailed SAR studies led to the discovery of compound 2 t, which exhibits excellent HPK1 inhibitory activity (IC = 1.
View Article and Find Full Text PDFTargeting hematopoietic progenitor kinase 1 (HPK1) for tumor immunotherapy: advances in small molecule inhibitors.
Biochem Pharmacol
August 2025
School of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai 201203, China. Electronic address:
Hematopoietic progenitor kinase 1 (HPK1), also known as MAP4K1, is a hematopoietic-specific serine/threonine kinase and a member of the MAP4K family of mammalian Ste20-associated protein kinases, which share a highly similar protein structure, and play important roles in the regulation of cell survival, cell migration, apoptosis and autophagy. HPK1 is a negative regulator of T-cell, B-cell and dendritic cell-mediated immune responses, and HPK1 kinase deficiency increases cytokine secretion and enhances T-cell signaling, viral clearance and tumor growth inhibition. Thus, HPK1 may be implicated in the development and progression of human malignant tumors and is a potent target for anti-tumor immunotherapy.
View Article and Find Full Text PDFUniversal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44 CD8 T cells in tumor-draining lymph nodes to enhance antitumor immunity.
J Immunother Cancer
July 2025
National Key Laboratory of Innovative Immunotherapy; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
Background: Immunocytokines targeting immune checkpoints have shown great potential in overcoming resistance to immune checkpoint blockade (ICB), making them a major focus of development in recent years. However, severe dose-limiting toxicity hindered their clinical application. Therefore, it is vital to develop versatile strategies to improve safety and elucidate the underlying mechanisms of resistance reversal for advancing immunocytokine therapy.
View Article and Find Full Text PDFDiscovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy.
J Med Chem
August 2025
School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Hematopoietic progenitor kinase 1 (HPK1), a negative regulator of the TCR signaling pathway, has emerged as an attractive drug target for tumor immunotherapy. Herein, we report the discovery of a series of pyrazine-based HPK1 PROTAC degraders. The representative compound demonstrated potent and sustained HPK1 degradation (DC = 5.
View Article and Find Full Text PDFHighly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade.
J Immunother Cancer
July 2025
Nimbus Therapeutics Inc, Boston, Massachusetts, USA
Background: HPK1 (hematopoietic progenitor kinase 1, MAP4K1), an MAP4K serine/threonine kinase family member, is a negative regulator of immune cell function. Genetic HPK1 kinase inactivation or knockout in mice leads to immune cell activation and tumor growth suppression, providing a strong rationale for targeting HPK1 kinase activity as an immuno-oncology therapy.
Methods: A structure-guided drug design approach was used to identify a highly potent and selective small molecule inhibitor of HPK1 kinase activity, NDI-101150.